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in a first step the concordance measure’s performance by 
(1) comparing the psychopathology patterns of 269 index 
cases suffering from functional psychoses with the respec-
tive patterns of the 350 “affecteds” among their first-degree 
relatives; (2) systematically comparing the psychopathol-
ogy patterns of 100 unrelated patients with a diagnosis of 
schizophrenic disorders with each other; and (3) detailing 
the within-pair concordance of elementary traits among 
2734 healthy twin pairs. As to the role of active immune 
processes in the context of schizophrenic disorders, we 
found that there exists a 20–30% subgroup of patients for 
whom aberrancies of the inflammatory response system, as 
quantified through IgM levels, appeared to be linked to the 
pathogenesis of schizophrenic disorders (r = 0.7515/0.8184, 
p < 0.0001). The variation of within-pair psychopathol-
ogy concordance among twins with schizophrenic dis-
orders was found to be “explainable” in part by chroni-
cally elevated IgM levels (24.5% of observed phenotypic 
variance; p = 0.0434), thus suggesting that monozygotic 
twins concordant for schizophrenic disorders may possess 
Abstract The concept of twin concordance involves 
quantifying the resemblance between co-twins in an 
“objective” and reproducible way. Yet, quantifying resem-
blance in the case of complex psychiatric traits like schizo-
phrenic disorders leads to methodological problems, as the 
yes–no dichotomy of diagnostic schemata does not allow 
one to assess between-subject differences in psychopathol-
ogy patterns sufficiently accurately. Therefore, we relied on 
a multidimensional, quantitative concordance measure that 
provided a high resolution and differentiation when assess-
ing the resemblance of psychopathology patterns. This con-
cordance measure was central to our investigations into the 
potential link between schizophrenic disorders and aber-
rancies of the inflammatory response system. Specifically, 
we aimed to determine the extent to which (1) the observed 
variation of between-subject psychopathology concordance 
among 100 schizophrenic patients and (2) the observed var-
iation of within-pair psychopathology concordance among 
71 twin pairs can be explained by immunoglobulin M 
(IgM) levels. To accomplish this goal, we had to “gauge” 
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a less “robust” variant of the inflammatory response sys-
tem which can more easily be triggered by exogenous fac-
tors than the more “robust” variants of discordant pairs. 
Though the underlying biological mechanisms remain to be 
detected, our data have cleared the way for an early identi-
fication of patients with schizophrenic disorders for whom 
the inflammatory response system may be a target for ther-
apeutic intervention. Moreover, our results will likely lead 
to new treatment strategies that involve elements of person-
alized medicine.
Keywords Twins · Within-pair concordance · 
Quantification · Psychopathology patterns · Inflammatory 
response system · Vulnerability
Background
The concept of twin concordance involves quantifying the 
resemblance between co-twins in an “objective” and repro-
ducible way. This leads to methodological problems in 
the case of complex traits, such as psychiatric diagnoses, 
symptoms, or syndromes, since the yes–no dichotomy of 
diagnostic schemata does not allow one to assess between-
subject differences in psychopathology patterns sufficiently 
accurately. Therefore, we relied on a multidimensional, 
quantitative concordance measure that provided a high res-
olution and differentiation when assessing the resemblance 
of psychopathology patterns. Our study laid its focus on 
schizophrenic disorders, a major diagnostic group in psy-
chiatry, and used the above concordance measure as a key 
tool when exploring the potential link between schizo-
phrenic disorders and aberrancies of the inflammatory 
response system.
The term “schizophrenia” was introduced more than 
100 years ago by Eugen Bleuler, then director of our hos-
pital [1]. The term denotes a group of complex, heteroge-
neous disorders of diverse etiopathology (“schizophrenic 
disorders” or, by E. Bleuler: “group of schizophrenias”). 
Schizophrenic disorders have a prevalence of about 1% in 
the general population worldwide, virtually independent of 
socio-cultural and ethnic differences. They cause the loss of 
the ability to work, to have close relationships, and to have 
a fulfilling life. Available treatments, though effective, are 
incomplete as treatment options are non-causal, and there is 
no cure for the majority of patients (50–60%).
Family studies suggest that schizophrenic disorders 
aggregate in families but do not segregate, that is, do not 
follow simple Mendelian modes of inheritance. Evidence 
for the involvement of genetic factors in the pathogenesis of 
schizophrenic disorders originated from studies of monozy-
gotic (mz) and dizygotic (dz) twins reared together [e.g., 2]: 
an average 55% of mz pairs were found to be concordant for 
schizophrenic disorders, compared to only 15% among the 
dz pairs, so that the question arises as to why mz co-twins 
reared in the same environment have a 3.7-fold higher risk 
to both suffer from schizophrenic disorders than do dz co-
twins. The answer to this question is genetics (or paternal 
epigenetic factors in mz twins only). Yet, these twin stud-
ies made it also clear that genetics can explain only part of 
the etiopathology as 45% of mz twins remain discordant for 
schizophrenic disorders over a lifetime, even though they 
share a common genome.
Active immune processes may be relevant for the devel-
opment of schizophrenic disorders (and major psychiat-
ric disorders in general), as suggested by evidence from 
recent studies. For example, (1) a population-based study 
of 7704 patients with a diagnosis of schizophrenic disor-
ders and 192,590 control subjects without psychiatric his-
tory has revealed that a parental history of schizophrenic 
disorders is associated with a fivefold risk for autoimmune 
diseases, whereas a parental history of autoimmune dis-
eases increased this risk only slightly, by a factor of 1.45 
[3]; (2) adiposity and inflammation appear to contribute to 
the development of depression [4]; (3) several antidepres-
sants and antipsychotics show anti-inflammatory effects 
[5–11]; (4) several studies demonstrated microglia activa-
tion and progressive brain changes in recent-onset schizo-
phrenia [12, 13]; (5) there is postmortem evidence of cer-
ebral inflammation in schizophrenia [14]; (6) significant 
alterations of T-cell function, along with activation of the 
inflammatory response system, appeared to be linked to 
treatment-resistant schizophrenia [3, 15]; and (7) similar 
processes have been reported for mood disorders as well 
[16–21].
The abnormalities of CNS metabolism observed with 
schizophrenic disorders or depression might, therefore, 
arise because genetically modulated inflammatory reac-
tions damage the microvascular system of the brain, with 
the nature of the infectious agent being less important than 
the patients’ genetically influenced inflammatory response 
[22]. Interestingly, the between-subject variation of the 
“natural” antibody immunoglobulin M1 (IgM) has been 
found to possess a strong genetic component [23], while 
chronically elevated IgM levels typically develop years 
before the first clinical symptoms occur [24].
Moreover, chronically elevated IgM levels appeared to 
be related to a heritable malfunction in the inflammatory 
response system [e.g., 23], and may even be linked to auto-
immune diseases in general. The pathogenesis of these 
1 IgM autoantibodies are proteins produced by the immune system in 
response to a perceived threat—which also may be the result of an 
aberrant immune response of the organism against its own cells and 
tissues (autoimmune inflammatory processes).
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latter diseases, however, is insufficiently understood, also 
because the question of autoantibody appearance prior to 
inflammation—indicating an antibody-driven inflamma-
tory response—could not yet be answered on the basis of 
empirical data.
To address the question of a potential link between 
schizophrenic disorders and aberrancies of the inflamma-
tory response, we “gauged” in a first normative step the 
performance of the multidimensional concordance meas-
ure by (1) comparing the psychopathology patterns of 269 
index cases suffering from functional psychoses with those 
of the 350 “affecteds” among their first-degree relatives; 
(2) comparing the psychopathology patterns of 100 unre-
lated patients with a diagnosis of schizophrenic disorders 
with each other; (3) detailing the within-pair concordance 
of elementary traits among 2734 healthy twin pairs; and (4) 
comparing the characteristics of the distribution of within-
pair IgM concordances with those of elementary traits.
Upon completion of the normative step, we were able 
to determine the extent to which (1) the observed varia-
tion of the between-subject psychopathology concordance 
among 100 schizophrenic patients and (2) the observed 
variation of the within-pair psychopathology concordance 
among 71 twin pairs were explainable by IgM levels. In 
addition, we searched for evidence supporting the hypoth-
esis that monozygotic twins concordant for schizophrenic 
disorders possess a less “robust” variant of the inflamma-
tory response system which can more easily be triggered by 
exogenous factors than the more “robust” variants of dis-
cordant pairs.
Methods
The concept of “concordance” deals with the degree of 
similarity between the two co-twins of a twin pair and 
the variation of that similarity across samples of mz and 
dz twins (“twin method”: used to estimate the geneti-
cally predisposed component of a trait). There are numer-
ous approaches to realizing the concept by quantifying 
within-pair similarities for traits, such as weight, height, 
brain-wave patterns, personality, behavior, or psychiat-
ric disorders, among others. The simplest way to address 
within-pair similarity of psychiatric disorders is based on 
clinical diagnosis and by just counting the number of twin 
pairs of a sample who share the same diagnosis (“concord-
ance rate”). The problem inherent in this approach lies in 
the yes/no-dichotomy of diagnostic systems which often 
means imposing structure on clinical data rather than find-
ing “natural” structure in the data. In the case of schizo-
phrenic disorders, this yes/no-dichotomy can yield con-
cordance rates in the range of 30–70% for the same sample 
of mz twins depending on the diagnostic system in use. 
And worst of all, one single item error on the diagnosis 
level can invert the entire outcome.
Another problem relates to the fact that the yes/no-
dichotomy approach to measuring concordance in twins 
with schizophrenic disorders has never been externally val-
idated or “gauged”. No information is available as to how a 
rate of “30%” derived through diagnostic system “A” for a 
given sample of twin pairs compares to the rate of “70%” 
derived for that sample through diagnostic system “B”; or 
how a rate of “45%” from hospital “C” compares to the 
rate of “55%” from hospital “D”. Nor do we know how all 
this compares to traits, such as height, weight, finger ridge 
count, brain waves, or behavior.
Quantitative concordance measures avoid these difficul-
ties. They are less error prone when assessing the within-
pair similarity of psychopathology among twin pairs with 
psychiatric disorders. In particular, they provide the meth-
odological framework for (1) more detailed investigations 
into twins with schizophrenic disorders and (2) the inclu-
sion of resilience factors which are likely to play a critically 
important role in the pathogenesis of these disorders.
In what follows, we will rely exclusively on quantitative 
concordance measures, so that we can analyze the distribu-
tion of within-pair concordances, can determine potential 
deviations from normality, and can use the respective mean 
values and standard deviations as estimates of the geno-
type–phenotype “distance” inherent in the trait under inves-
tigation. We also think that it is absolutely necessary to 
externally validate and to calibrate a methodological frame-
work prior to applying it to schizophrenia data. Therefore, 
normative analyses are part of this manuscript.
The psychopathology assessments of this study were 
based on the syndrome-oriented instruments SSCL-16 and 
SSCL-16 Supplement which extend the DSM-V and ICD-
10 definitions of psychiatric disorders by replacing the 
yes–no dichotomy of diagnostic schemata by dimensional 
quantities, thus enabling the inclusion of details of psycho-
pathology patterns that do not reach diagnostic thresholds 
and would otherwise be ignored. The instruments2 were 
developed by Angst et al. [25] from the lifetime version of 
the “Schedule for Affective Disorders and Schizophrenia 
(SADS-L)” [26]. The SSCL-16 assesses 16 syndromes in a 
quantitative way through the respective symptoms. Key to 
schizophrenic disorders are the SSCL-16 syndromes “schiz-
ophrenic thought disorders”, “delusions”, “hallucinations”, 
“ego consciousness”, “anergia”, “incongruent affect”, 
“depressive syndrome”, “manic syndrome”, and “attempted 
suicide”. The SSCL-16 is complemented by the SSCL-16 
Supplement which measures the patients’ “overall level of 
functioning”, “social relations”, “affective lability”, 
2 Available on website “http://www.bli.uzh.ch/Left07b.php”.
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“personality traits”, “somatization”, and “consumption 
behavior”. Our study was comprised of four independent 
samples:
1. 269 patients suffering from functional psychoses 
(schizophrenic-, schizoaffective-, bipolar disorders, 
and depression with psychotic symptom) along with 
the 350 “affecteds” among their 1501 first-degree rela-
tives (143 males, 207 females; 124 fathers and mothers 
with a mean age of 64.6 years; and 226 siblings with 
a mean age of 34.8 years). This sample was recruited 
from consecutive admissions to our hospital. The sub-
jects’ psychopathology (lifetime) was assessed through 
the SSCL-16 and SSCL-16 Supplement instruments by 
specifically trained interviewers. Details are given in 
Table 1.
2. 100 patients randomly selected from our databank with 
an ICD10 diagnosis of schizophrenic disorders (50 
males, 50 females). The patients’ psychopathology 
(lifetime) was assessed through the SSCL-16 and 
SSCL-16 Supplement instruments by specifically 
trained interviewers. The patients contributed a 
2 × 9  ml blood sample from which DNA and serum 
were extracted, so that IgM3 levels and cytokine data4 
(Il-6, TNF-a, Neopterin, TGF-β1, and sCD14) could be 
measured.
3. 2734 healthy twin pairs5 serving as “learning” basis for 
our investigations into the within-pair concordance of 
twins with schizophrenic disorders: 1434 monozygotic 
pairs (592 male pairs, 842 female pairs) with a mean 
age of 38.3 ± 6.9  years and 1300 same-sex dizygotic 
3 IgM levels were determined by the Viollier Laboratories, Basel.
4 Data courtesy Müller N. and Schwarz M.
5 Data courtesy David T. Lykken.
pairs (514 male pairs, 786 female pairs) with a mean 
age of 39.2 ± 6.9 years. The data allowed us to “gauge” 
the characteristic variation of within-pair concordance 
measures for elementary traits, such as height, weight, 
shoe size, finger ridge count, birthweight, among oth-
ers.
4. Pilot sample of 47 monozygotic and 24 dizygotic 
same-sex twin pairs. The twins’ psychopathology (life-
time) was assessed through the SSCL-16 and SSCL-16 
Supplement instruments by specifically trained inter-
viewers. All subjects contributed a 2 × 9 ml blood sam-
ple from which DNA and serum were extracted, so 
that IgM levels and cytokine data could be measured. 
Of this sample, 28 pairs had at least one co-twin who 
received an ICD10 diagnosis of schizophrenic disor-
ders. The other pairs did not meet the criteria of schiz-
ophrenic disorders and received either other diagnoses 
or no diagnosis. Zygosity was determined by a set of 
five highly polymorphic dinucleotides and confirmed 
by 448 SNPs.
Quantifying within‑pair concordance among twins
The most popular concordance measure for single quantita-
tive traits is the Pearson product-moment correlation coef-
ficient which measures the linear correlation between co-
twins for a given variable of interest, such as body height, 
body weight, etc. For a set of n monozygotic or dizygotic 
twin pairs, this correlation coefficient r(x,y) is calculated 
through the following formula (1):
where x denotes the variable value of the first co-twin and y 
denotes the variable value of the second co-twin. The run-
ning index “i” indicates that the formula evaluates the vari-
able values x,y for the set of n twin pairs as an entity. For 
(1)
r(x,y) =
1
n − 1
n∑
i=1
(
xi − x̄
sx
)(
yi − ȳ
sy
)
x̄ =
1
n
n∑
i=1
xi sx =
√√√√ 1
n − 1
n∑
i=1
(xi − x̄)
2
ȳ =
1
n
n∑
i=1
yi sy =
√√√√ 1
n − 1
n∑
i=1
(yi − ȳ)
2,
Table 1  Sample composition 
of the zurich psychosis study 
regarding index cases (n = 269)
Total Males Females Age (years) Range (years)
Schizophrenic disorders 140 66 74 35.6 ± 11.7 17–73
Schizoaffective disorders 43 14 29 47.0 ± 12.3 19–69
Bipolar disorders 34 17 17 47.3 ± 15.9 17–72
Depression with psychotic symptoms 52 26 26 55.1 ± 11.3 20–76
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sufficiently large samples of twin pairs, the between-pair 
variation along with confidence intervals can be estimated 
by means of random sampling methods. Here, the corre-
lation coefficient is computed for randomly selected sub-
samples comprising about 10% of the total sample. This is 
repeated a large number of times (“bootstrapping”).
Alternatively, the Intraclass Correlation (ICC) can be 
used to quantify the degree to which co-twins resemble 
each other in terms of a quantitative trait. The ICC operates 
on data structured as groups, rather than data structured 
as paired observations. In consequence, the ICC approach 
is the perfect method for the assessment of consistency 
of quantitative measurements made by several different 
observers measuring the same quantity. The ICC is calcu-
lated through the following formula (2):
where x1 denotes the variable value of the first co-twin 
and x2 denotes the variable value of the second co-twin. 
The running index “i” indicates that the formula evaluates 
the variable values for a set of n twin pairs as an entity. 
The differences between Pearson and ICC coefficients are 
marginal for elementary traits, such as height, weight, shoe 
size, birth weight, or the BMI (in the range of 1–2%). A 
disadvantage is that the ICC is only rudimentarily sup-
ported by the statistics packages SAS and SPSS.
Multidimensional approach
If several variables have to be evaluated simultaneously, as 
is the case for schizophrenic disorders quantified through a 
set of syndromes, the standard choice is the “Euclidean 
Distance” which measures “discordance”6 between co-
(2)
r(x1,x2) =
1
Ns2
N∑
i=1
(xi,1 − x̄)(xi,2 − x̄) x̄ =
1
2N
N∑
i=1
(xi,1 + xi,2)
s2 =
1
2N
{
N∑
i=1
(xi,1 − x̄)
2
+
N∑
i=1
(xi,2 − x̄)
2
}
,
6 “Concordance” and “discordance” are inversely related to each 
other.
twins, or between pairs of subjects, through the square root 
of the sum of squares of variable differences (3):
where ⇀x denotes the multidimensional set of variables of 
the first co-twin and ⇀y that of the second co-twin. If the 
variables differ significantly with respect to range and 
magnitude, the Euclidean Distance has to be “normal-
ized” or “standardized” to avoid situations where one vari-
able “overpowers” all others. Normalization is achieved by 
dividing each variable’s difference either by the absolute 
range or the standard deviation of the respective kth vari-
able, calculated across all co-twins (4):
(3)
d(
⇀
x,
⇀
y) =
√√√√ n∑
k=1
(xk − yk)
2 ⇀x = (x1,x2,… xn)
⇀
y = (y1,y2,… yn),
(4)
dn(
⇀
x,
⇀
y) =
√√√√ n∑
k=1
(xk − yk)
2
sk
sk =
√√√√ 1
2n − 1
n∑
i=1
{
(xk
i
− x̄k)
2
+ (yk
i
− x̄k)
2
}
kth vector component
x̄k =
1
2n
n∑
i=1
(xk
i
+ ȳk
i
) kth vector component,
where “dn(⇀x,⇀y)” denotes the normalized Euclidean Distance 
with ⇀x being the multidimensional set of variables of the 
first co-twin and ⇀y that of the second co-twin. The multi-
variate concordance measure s(⇀x,⇀y) is derived directly from 
the Euclidean Distance through formula (5).
Statistical analyses
Statistical analyses were carried out by means of the Sta-
tistical Analysis Software SAS/STAT 9.3 [PROCs FREQ, 
MEANS, CORR, REG, and GLM (unbalanced data)], 
while a proprietary program of our institute was used for 
random sampling and the generation of postscript plots.
The study was approved by the local ethics committees 
and written informed consent was obtained from all par-
ticipants. There are no conflicts of interest.
(5)s(
⇀
x,
⇀
y) =
1
d(
⇀
x,
⇀
y) + 1
,
382 Eur Arch Psychiatry Clin Neurosci (2017) 267:377–389
1 3
Results
Index cases with schizophrenic disorders 
versus affected first‑degree relatives
Quite a number of diagnosis-oriented family studies of 
schizophrenic disorders have demonstrated that there 
is no homotypal similarity between index cases suf-
fering from schizophrenic disorders and their affected 
first-degree relatives in the sense that the index case’s 
clinical diagnosis predominantly occurs among family 
members, irrespective of the diagnostic schema in use. 
On the syndrome level, by contrast, our quantitative anal-
ysis revealed highly significant similarities (p < 0.001) 
between the syndrome profiles of index cases of the 
“Schizophrenia Cluster” (n = 136) and the syndrome 
profiles of their affected first-degree relatives (n = 116) 
(Fig. 1).
This finding suggested that studies of schizophrenic 
disorders which exclusively rely on clinical diagnoses are 
likely to suffer the loss of critically important information, 
and may obscure the “true” nature of this group of hetero-
geneous disorders of diverse etiopathology (E. Bleuler: 
“group of schizophrenias”).
Calibration sample of 100 patients with an ICD10 
diagnosis of schizophrenic disorders
On the diagnostic level, all possible comparisons between 
patients with the same psychiatric diagnosis necessar-
ily yield concordances of 100%. By contrast, quantitative 
psychopathology scores as derived from the SSCL-16 and 
SSCL-16 Supplement allow one to study the between-
patient concordance at high resolution and differentiation, 
so that the specifics of individual psychopathology patterns 
are revealed. We formed all n × (n − 1)/2 = 4950 possible 
pairings of the patients and calculated the between-patient 
concordances for several quantitative syndrome profiles 
that describe schizophrenic disorders at different levels of 
detail. Special focus was laid on the differences in psycho-
pathology regarding clinical picture, severity of illness, age 
of onset, and response to treatment. All these aspects can 
differ greatly between patients despite the fact that all have 
received the same psychiatric diagnosis.
Concordance analyses for all syndrome profiles under 
investigation yielded approximately normal distributions 
with surprisingly robust and virtually identical concord-
ance rates. The mean values lay around 0.536 ± 0.091 (con-
cordance 53.6%), as long as the key syndromes of schizo-
phrenic disorders were part of the profiles. As one would 
expect, the more details on clinical picture, severity, onset, 
and response to treatment were included, the broader the 
observed range of variation in between-patient concordance 
(Fig.  2). Most interestingly, the observed between-patient 
concordances were almost identical with the within-pair 
concordances reported in the literature for mz twins (55%).
For the sample as a whole entity, our analyses yielded 
no significant correlations between IgM levels and psy-
chopathology syndrome scores. However, it was readily 
possible (through the selection of suitable cases) to “con-
struct” a 20–30% subgroup for which significant correla-
tions showed up. A simple IgM cut-off value turned out to 
be insufficient for this selection. We used instead a stand-
ard neural network classifier as a more reliable approach to 
Fig. 1  Highly significant 
similarity (p < 0.001) between 
the SSCL-16 syndrome profiles 
derived by averaging across 
index cases of the “Schizo-
phrenia Cluster” (n = 136; 
green bars) and the SSCL-16 
syndrome profiles derived by 
averaging across their “affected” 
first-degree relatives (n = 116; 
red bars). On the diagnosis 
level, by contrast, no homo-
typal similarity between index 
cases and first-degree relatives 
was found in the sense that the 
index cases’ clinical diagnoses 
predominantly occur among 
members of their families (total 
sample size: 269 index cases 
along with 350 “affecteds” 
among their first-degree rela-
tives)
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identifying patients with the highest association between 
IgM levels on the one hand, and all four scores of the core 
syndromes of schizophrenic disorders on the other (schizo-
phrenic thought disorders, delusions, hallucinations, and 
ego consciousness).
The algorithm adjusted the group size while maximizing 
the IgM-syndrome correlations for the group as an entity. 
The procedure yielded the following correlations (group 
size 25, nonparametric Spearman Rank): for “schizophrenic 
thought disorders” r = 0.7515, p < 0.0001; for “delusions” 
0.5251, p < 0.007; for “hallucinations” 0.5320, p < 0.006; 
and for “ego consciousness” r = 0.8184, p < 0.0001. The 
other syndrome correlations did not reach statistical sig-
nificance: “anergia” (r = −0.1867), “incongruent affect” 
(r = 0.1478), and “depressive syndrome” (r = −0.1270).
None of the cytokines under investigation had a signif-
icant influence on the observed IgM levels, thus suggest-
ing that acute infections played a minor role in this patient 
sample, if at all. In consequence, the combined assessment 
of SSCL-16 syndrome scores and IgM levels apparently 
enables the early identification of that 20–30% subgroup of 
patients for whom the inflammatory response system might 
be a target for therapeutic intervention.
Normative sample of 2734 healthy twin pairs
As to directly assessable elementary traits, it is interest-
ing to note that monozygotic (mz) and dizygotic (dz) 
concordances reported in the literature are given as bare 
mean values. No information is available about the sta-
tistical distributions of mz and dz concordances which 
may be non-normal. To address this issue, we calculated 
within-pair concordances separately for males and females 
based on formula (1) in combination with a bootstrapping 
approach (1000 randomly selected subsamples comprising 
5–8% of each subset of twin pairs defined by gender and 
zygosity). We found, for example, normal distributions for 
body height and body weight (Fig. 3).
In detail, the mean concordance rates were 0.891 (mz; 
concordance 89.1%) and 0.448 (dz; concordance 44.8%) 
for variable “body height”, and 0.781 (mz; concordance 
78.1%) and 0.388 (dz; concordance 38.8%) for variable 
“body weight”, respectively. In particular, the mean con-
cordance rates of both variables did not show gender differ-
ences and displayed a mz:dz ratio of exactly 2:1 independ-
ent of the actual magnitudes. Mean values and standard 
deviations were inversely related to each other: the larger 
the mean value the smaller the standard deviation. Using 
the same method of approach, we subsequently determined 
the distributions of mz and dz concordances for additional 
elementary traits. Again, no gender differences were found 
(Fig. 4).
The numerical results from these analyses are sum-
marized in Table  2. The most unexpected result was that 
all variables showed a mz:dz ratio of exactly 2:1 indicat-
ing polygenic additive modes of inheritance. The variable 
“birthweight” was the only exception with a mz:dz ratio 
of 1:1, thus suggesting that environmental factors played a 
dominant role for this variable and obscured genetic predis-
position (Table 2).
Contrary to expectations, we did not find a significantly 
reduced within-pair concordance in dz twin pairs for the 
variable “body weight”, despite major environmental chal-
lenges over 10–15 years after adolescence, accentuated by 
the fact that many co-twins lived separated from each other 
in different environments (with different partners) for quite 
a number of years. Hence, environmental factors appeared 
to have a small impact compared to the dominating genetic 
component.
Fig. 2  Variation of between-subject concordances of n = 100 unre-
lated subjects with a diagnosis of schizophrenic disorders. Concord-
ances were calculated for all n × (n − 1)/2 = 4950 possible pairings 
and for the two combined quantitative SSCL-16 syndromes “schizo-
phrenic thought disorders” and “depressive syndrome” (upper left) 
and for the four combined quantitative SSCL-16 syndromes “schizo-
phrenic thought disorders”, “delusions”, “hallucinations”, and “ego 
consciousness” (upper right). The mean concordance rates were vir-
tually identical, while the range of variation increased with the num-
ber of syndromes
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Once the normative analyses were completed, we calcu-
lated the between-patient IgM concordances for all possible 
pairings of the 100 patients with a diagnosis of schizophrenic 
disorders. Using the same methodological framework as in 
the normative analyses (random sampling: Pearson product-
moment coefficient with “bootstrapping”), we found a right-
skewed distribution whose characteristics differed substan-
tially from those of the model traits “body height” and “body 
weight”. This finding suggested the existence of principal 
differences in the underlying biological mechanisms. The 
observed skewness was due to the fact that the patient popu-
lation encompassed two subgroups: (1) more than 70% of the 
patients had very low IgM levels (first subgroup), whereas 
(2) the other 30% of patients exhibited somewhat elevated 
levels (second subgroup) with cut-off set to IgM ≥13.5 (cf. 
[23]). Clearly, concordances calculated between patients of 
the same subgroup were much higher than those calculated 
between patients of different subgroups (Fig. 5).
Pilot sample of twins concordant and discordant 
for schizophrenic disorders
For schizophrenic disorders, the most frequently reported 
and generally accepted concordance rates for mz and dz 
twin pairs show substantial deviations from the mz:dz ratio 
of 2:1. Specifically, mz co-twins reared in the same envi-
ronment are reported to have a concordance rate of 0.55 
(55%), whereas dz co-twins reared in the same environment 
are reported to show a concordance rate of only 0.15 (15%). 
To address the question of the extent to which the variation 
of within-pair psychopathology concordance is explainable 
through IgM levels, we applied the multidimensional quan-
titative concordance measure to our pilot sample of twins 
concordant and discordant for schizophrenic disorders. In 
particular, we determined the within-pair concordances of 
mz and dz twins for the various psychopathology syndrome 
profiles under investigation as well as for the IgM levels.
Contrary to expectations, we found a mz:dz ratio of 
almost exactly 2:1 for the syndrome profiles made up by 
the SSCL-16 syndromes “schizophrenic thought disorders”, 
“delusions”, “hallucinations”, “ego consciousness”, “aner-
gia”, “incongruent affect”, and “depressive syndrome” 
with mean values of 0.5408 ± 0.1708 (mz pairs; concord-
ance 54.08%) and 0.2728 ± 0.0752 (dz pairs; concordance 
27.28%). The mz:dz ratio of 2:1 turned out to be very 
robust when adding single syndromes to, or removing sin-
gle syndromes from, the profile (Fig. 6).
Fig. 3  Within-pair concordances of model traits “body height” 
(upper half) and “body weight” (lower half) for monozygotic (mz: 
red) and dizygotic (dz: green) twins. The distributions were cal-
culated separately for males and females to detect potential gender-
related differences, but no such differences were found. The empirical 
distributions are approximately normally distributed as demonstrated 
through the black distribution curves on the right side
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The within-pair psychopathology concordances among 
the mz pairs of our pilot sample varied across the interval 
(0.281–0.656), that is, exhibited a remarkably broad range 
from “discordant” to “concordant” without, however, 
reaching “perfect” discordance or concordance. In fact, 
there was not a single mz pair in our sample that displayed 
perfect concordance regarding schizophrenic disorders7. 
The within-pair concordances in terms of IgM levels 
showed with 0.7480 ± 0.1362 (mz pairs; concordance 
74.8%) and 0.5086 ± 0.2750 (dz pairs; concordance 
50.86%) significant deviations from the expected 2:1 ratio, 
thus suggesting that IgM levels, regarded as dynamic sys-
tem outputs, were at least for some of the twin pairs not in 
“baseline position”. This in turn suggested the existence of 
7 This is different from the qualitative diagnosis-oriented approach 
where co-twins who both meet the diagnostic threshold are deemed 
to be perfectly concordant (100%) irrespective of differences in their 
psychopathology pattern. Analogously, if one co-twin does not meet 
the diagnostic criteria and the second co-twin does, the pair is treated 
as perfectly discordant.
Fig. 4  Distributions of the within-pair concordances of the quan-
titative traits “finger ridge count” (upper left), “body height” (upper 
right), “brain wave patterns” (lower left), and “body weight” (lower 
right) presented as ideal normal distributions N(µ,σ) with mean “µ” 
and standard deviation “σ”. The distribution curves of monozygotic 
(mz) twins are in red and those of the dizygotic (dz) twins in green. 
Differences between traits relate to differences in µ and σ, with µ and 
σ being inversely related to each other: the larger the observed µ the 
smaller the corresponding σ. The means of all four traits exhibit a 
mz:dz ratio of 2:1
Table 2  Quantitative traits “finger ridge count”, “body height”, 
“brain wave patterns”, “shoe size”, and “body weight” display mean 
concordance rates for monozygotic (mz) and dizygotic (dz) twin pairs 
which have a mz:dz ratio of 2:1 irrespective of the actual magnitude
The only exception is “birthweight” with an mz:dz ratio of 1:1. Devi-
ations from the expected ratio of 2:1 indicate the existence of strong 
endogenous or exogenous factors that modify the trait under com-
parison for both co-twins in likewise ways. Pearson correlation coef-
ficients were chosen, because (1) the differences between Pearson and 
ICC are marginal for these traits, in the range of 1–2%; and (2) the 
ICC is only rudimentarily supported by the standard statistics pack-
ages SAS and SPSS and is, therefore, not readily available to people 
interested in verifying these results
mz twins dz twins
Within-pair concordance of quantitative traits
 Finger ridge count 0.990 0.500
 Body height 0.891 0.448
 Brain wave patterns 0.824 0.415
 Shoe size 0.875 0.454
 Body weight 0.781 0.388
 Birth weight 0.695 0.694
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bodily responses to or interactions with endogenous or 
exogenous factors (as was the case with variable 
“birthweight”).
Finally, we applied a General Linear Model (GLM) to 
the mz pairs’ psychopathology and IgM data to estimate 
the extent to which the variation of within-pair psycho-
pathology concordance among mz twins with schizo-
phrenic disorders was “explainable” through chroni-
cally elevated IgM levels. Syndrome profiles were made 
up again by the SSCL-16 syndromes “schizophrenic 
Fig. 5  Distribution of between-subject IgM concordances was 
found to be right-skewed and showed a broad range of variation 
among the n = 100 patients with schizophrenic disorders (total 
n × (n − 1)/2 = 4950 possible pairings). The characteristics differed 
completely from those of the model traits “body height” and “body 
weight”, thus suggesting the existence of principal differences in the 
underlying biological mechanisms. The observed skewness was due 
to the fact that the population encompassed two subgroups: more than 
70% of the patients had very low IgM levels, whereas the other 30% 
of patients exhibited somewhat elevated levels. Therefore, concord-
ances calculated between patients of the same subgroup were higher 
than those calculated between patients of different subgroups
Fig. 6  Within-pair concord-
ances in terms of the psychopa-
thology profile made up by the 
SSCL-16 syndromes “schizo-
phrenic thought disorders”, 
“delusions”, “hallucinations”, 
“ego consciousness”, “aner-
gia”, “incongruent affect”, and 
“depressive syndrome”. We 
found a mz:dz ratio of 2:1 with 
mean values of 0.5408 ± 0.1708 
for the monozygotic (mz) pairs 
and 0.2728 ± 0.0752 for the 
dizygotic (dz) pairs. This mz:dz 
ratio turned out to be very 
robust in regard to adding addi-
tional syndromes to or remov-
ing single syndromes from the 
profile. The sample sizes are 
by far too small to reveal the 
underlying normal distributions
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thought disorders”, “delusions”, “hallucinations”, “ego 
consciousness”, “anergia”, “incongruent affect”, and 
“depressive syndrome”. The fitted GLM (simple regres-
sion) used “IgM level” as independent and “within-
pair concordance” as dependent variable. The variable 
“sex” was removed from the model due to nonsignifi-
cant influence (p = 0.163). The fitted model included 
all 17 mz pairs with at least one co-twin suffering from 
schizophrenic disorders, reached statistical significance 
(p = 0.0434; F = 4.87/1 DF), and explained 24.5% of the 
observed phenotypic variance. The IgM intercept was 
0.505 (p < 0.0001; t = 12.45/1 DF). No such model was 
found for the dz pairs.
Discussion
Evidence from an increasing number of studies has sug-
gested that active immune processes are likely involved in 
the pathogenesis of schizophrenic disorders, or even psy-
chiatric disorders in general [4–14, 17, 18, 23, 27–30]. This 
raised the intriguing question of whether or not the dif-
ferences between mz twins concordant and mz twins dis-
cordant for schizophrenic disorders might be linked to the 
“robustness” of the inflammatory response system. This in 
the sense that mz co-twins concordant for schizophrenic 
disorders possess a less “robust” variant of the inflamma-
tory response system that can more easily be triggered by 
endogenous and exogenous factors than the more “robust” 
variants of discordant pairs.
To accomplish this goal, we replaced the yes–no dichot-
omy of the diagnostic schemata by dimensional quantities, 
that is, we replaced the uninformative “100%” concord-
ances on the diagnosis level by multidimensional quanti-
ties. This quantitative approach allowed us to analyze inter-
individual psychopathology differences among patients 
with the same clinical diagnoses. In fact, details of psycho-
pathology patterns that did not reach diagnostic thresholds 
would have been ignored otherwise.
Our results suggested that perfect concordance (100% 
identity) is a theoretical concept rarely ever observed 
among patients with the same psychiatric diagnosis or 
among pairs of mz twins. Rather, quantitative traits show 
approximately normal distributions N(µ,σ) with mean 
“µ” and standard deviation “σ”, such that 65% of the twin 
pairs exhibit concordances in the range of µ ± σ and 95% 
in the range of µ ± 2σ. Differences between traits are solely 
reflected by differences in µ and σ, with µ and σ being 
inversely related to each other: the larger the observed µ 
the smaller the corresponding σ. In addition, typically, the 
more details of a complex trait are covered by a multidi-
mensional concordance measure the smaller the observed 
µ.
Almost identical concordance rates for between-patient 
and within-pair mz twin comparisons indicated that we 
were dealing with an average “random” sample of mz twins 
suffering from schizophrenic disorders—without selection 
bias towards more concordant or more discordant pairs. 
In consequence, the epidemiology of within-pair psycho-
pathology concordance among mz twins seems to be best 
described by a normal distribution, as shown in Fig.  2. 
Moreover, we expect that such “normal” psychopathol-
ogy distributions apply for twins with psychiatric disorders 
in general, with higher concordance rates when twins are 
ascertained through more severe forms of psychiatric dis-
orders. Taken together, this allows us to conjecture that 
the genetics involved in schizophrenic disorders acts in the 
sense of an unspecific vulnerability which is neither a nec-
essary nor a sufficient condition for developing the illness.
This study provided two independent lines of evidence 
suggesting that genetically influenced aberrancies of the 
inflammatory response system contribute to this unspecific 
vulnerability, at least in a 20–30% subgroup of patients suf-
fering from schizophrenic disorders. Our findings from the 
calibration sample of 100 patients with an ICD10 diagnosis 
of schizophrenic disorders might have cleared the way for 
an early identification of patients for whom the inflamma-
tory response system is a target for therapeutic intervention 
[31]. Once successfully established, the proposed method 
of approach will enable new treatment strategies involving 
elements of personalized medicine. This is of major interest 
for patients, psychiatrists, and other health care providers 
as currently available treatment options offer only modest 
efficacies and, most importantly, do not allow one to make 
any predictions of whether or not a particular patient will 
respond to a particular treatment or will experience certain 
unwanted side effects. Given the study results, an estimated 
20–30% of patients with schizophrenic disorders may ben-
efit from such new treatment strategies.
This study complemented two previous twin studies 
where co-twins concordant for schizophrenic disorders 
exhibited a significantly reduced—rather than increased—
within-pair concordance for brain wave patterns. This 
unexpected finding had led to the hypothesis that nonge-
netic pathologic processes alter the co-twins’ genetically 
identical brains in such a way that pathologically different 
functional changes can develop in the co-twins [32, 33]. It 
remains an open question, however, whether these func-
tional changes can be linked to aberrancies of the inflam-
matory response system.
The pilot sample of 47 mz and 24 dz same-sex twin 
pairs was by far too small to draw definitive conclusions 
regarding the extent to which active immune processes are 
involved in the pathogenesis of schizophrenic disorders. In 
particular, the question of whether or not the differences 
between mz twins concordant and mz twins discordant for 
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schizophrenic disorders might be linked to the “robust-
ness” of the inflammatory response system could not be 
answered in a definite way. Comorbid disease processes 
might explain our findings as well.
Another limitation relates to the fact that psychopathol-
ogy assessments on family members of index cases typi-
cally yield a less severe clinical picture compared to that of 
the acutely ill and hospitalized index cases. Most family and 
twin studies show this phenomenon which is likely an artifact 
due to the differences in the amount and quality of available 
information on psychiatric episodes in the past. However, the 
possibility of a “true” effect of this kind cannot be ruled out 
on the basis of empirical data. Similarly, the observation that 
females were more likely to participate in our studies than 
males (both index cases and relatives) must not necessarily 
have introduced an unwanted bias into the data but, rather, 
may be an intrinsic property of schizophrenic disorders.
Conclusions
Using a study design with four independent samples, our 
results provided two independent lines of evidence for an 
involvement of the inflammatory response system in the 
pathogenesis of schizophrenic disorders: (1) there existed a 
20–30% subgroup of patients for whom aberrancies of the 
inflammatory response system appeared to be linked to the 
pathogenesis of schizophrenic disorders (r = 0.7515/0.8184, 
p < 0.0001) and (2) the variation in mz concordance regard-
ing schizophrenic disorders was in part “explainable” 
through chronically elevated IgM levels (24.5% of observed 
phenotypic variance; p = 0.0434). Though the underly-
ing biological mechanisms remain to be detected, our data 
have cleared the way for an early identification of patients 
with schizophrenic disorders for whom the inflammatory 
response system may be a target for therapeutic interven-
tion. We expect that this finding will lead to new treatment 
strategies that have their focus on a personalized medicine.
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